Myomo, Inc.

MYO · NYSE · ·

Karşılaştır

$1,23+%2,513 Kas kapanış

30 Eylül 2026 tarihine kadarki rakamlar, 9 Kasım 2026 tarihinde sunulan 10-Q raporundan

1W: +%1,7
1M: -%0,8

Just reported

Q3 2026 results

From Myomo's results release of 9 Kasım 2026; its quarterly report has since been filed.

Revenue
Actual
$12,3M
+%22 y/y
+%5,3 q/q
Guided
$11,8M
midpoint
Above guide+%4,9
EPS, GAAP
Actual
-$0,10
Guided
—
No guide given
Operating income, GAAP
Actual
-$1,7M
Guided
—
No guide given

Company outlook

Full year 2026

Revenue$46M – $47M+%14 y/y Raised +%1,1

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Myomo is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Medical Devices

Graded A or B and worth $2B or more: A first, then the largest.

All 133 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Tüm finansal tablolar →

Myomo, Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.

Myomo, Inc.

Myomo, Inc.

Q3 2026 results

Revenue

EPS, GAAP